Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Psychiatria
MENU
Na skróty Zdeponuj artykuł Wytyczne dla autorów Ahead of print Recenzenci 2022 Kolegium redakcyjne

dostęp otwarty

Tom 14, Nr 4 (2017)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2017-11-30
Pokaż PDF Pobierz plik PDF
Pobierz cytowanie

Połączenie wielonienasyconych kwasów tłuszczowych oraz kwasu alfa-liponowego (Liponerv®) w łagodnych zaburzeniach poznawczych

Bernard Dżumaga1
Psychiatria 2017;14(4):255-261.
Afiliacje
  1. Qpharma Sp. z o.o., Warszawa, Polska

dostęp otwarty

Tom 14, Nr 4 (2017)
Opinia eksperta
Opublikowany online: 2017-11-30

Streszczenie

brak

Streszczenie

brak

Pełny tekst:

Pokaż PDF Pobierz plik PDF
Pobierz cytowanie

Słowa kluczowe

brak

Informacje o artykule
Tytuł

Połączenie wielonienasyconych kwasów tłuszczowych oraz kwasu alfa-liponowego (Liponerv®) w łagodnych zaburzeniach poznawczych

Czasopismo

Psychiatria

Numer

Tom 14, Nr 4 (2017)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

255-261

Opublikowany online

2017-11-30

Wyświetlenia strony

406

Wyświetlenia/pobrania artykułu

3179

Rekord bibliograficzny

Psychiatria 2017;14(4):255-261.

Słowa kluczowe

brak

Autorzy

Bernard Dżumaga

Referencje (42)
  1. Reisberg B, Ferris S, Leon Mde, et al. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Development Research. 1988; 15(2-3): 101–114.
    CrossRef
  2. Carrasquillo MM, Crook JE, Pedraza O, et al. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997; 9 Suppl 1(7): 65–69.
    PubMed
  3. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003; 2(1): 15–21.
    PubMed
  4. Unverzagt FW, Gao S, Baiyewu O, et al. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology. 2001; 57(9): 1655–1662.
    PubMed
  5. Okhravi HR, Palmer RM. Mild cognitive impairment: challenges in research and in practice. Cleve Clin J Med. 2012; 79(12): 853–854.
    CrossRefPubMed
  6. Barberger-Gateau P, Letenneur L, Deschamps V, et al. Fish, meat, and risk of dementia: cohort study. BMJ. 2002; 325(7370): 932–933.
    PubMed
  7. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology. 2007; 69(20): 1921–1930.
    CrossRefPubMed
  8. van Gelder BM, Tijhuis M, Kalmijn S, et al. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007; 85(4): 1142–1147.
    PubMed
  9. Morris MC, Evans DA, Tangney CC, et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol. 2005; 62(12): 1849–1853.
    CrossRefPubMed
  10. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006; 63(11): 1545–1550.
    CrossRefPubMed
  11. Boston PF, Bennett A, Horrobin DF, et al. Ethyl-EPA in Alzheimer's disease--a pilot study. Prostaglandins Leukot Essent Fatty Acids. 2004; 71(5): 341–346.
    CrossRefPubMed
  12. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006; 63(10): 1402–1408.
    CrossRefPubMed
  13. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010; 304(17): 1903–1911.
    CrossRefPubMed
  14. Yurko-Mauro K, McCarthy D, Rom D, et al. MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010; 6(6): 456–464.
    CrossRefPubMed
  15. Vakhapova V, Cohen T, Richter Y, et al. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord. 2010; 29(5): 467–474.
    CrossRefPubMed
  16. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1538–1544.
    CrossRefPubMed
  17. Lee LK, Shahar S, Chin AV, et al. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2013; 225(3): 605–612.
    CrossRefPubMed
  18. Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr. 2012; 107(11): 1682–1693.
    CrossRefPubMed
  19. Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006; 56(2): 159–164.
    CrossRefPubMed
  20. Mazereeuw G, Lanctôt KL, Chau SA, et al. Effects of ω-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging. 2012; 33(7): 1482.e17–1482.e29.
    CrossRefPubMed
  21. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr. 2010; 140(4): 869–874.
    CrossRefPubMed
  22. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids. 2009; 81(2-3): 213–221.
    CrossRefPubMed
  23. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev. 2008; 60(13-14): 1463–1470.
    CrossRefPubMed
  24. Hager K, Kenklies M, McAfoose J, et al. Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. J Neural Transm Suppl. 2007(72): 189–193.
    PubMed
  25. Fava A, Pirritano D, Plastino M, et al. The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease. J Neurodegener Dis. 2013; 2013: 454253.
    CrossRefPubMed
  26. Shinto L, Quinn J, Montine T, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis. 2014; 38(1): 111–120.
    CrossRefPubMed
  27. Hjorth E, Zhu M, Toro VC, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013; 35(4): 697–713.
    CrossRefPubMed
  28. Puskás LG, Kitajka K, Nyakas C, et al. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci U S A. 2003; 100(4): 1580–1585.
    CrossRefPubMed
  29. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem. 2007; 101(3): 577–599.
    CrossRefPubMed
  30. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol . 2010; 177: 1576–1591.
  31. Tanaka K, Farooqui AA, Siddiqi NJ, et al. Effects of docosahexaenoic Acid on neurotransmission. Biomol Ther (Seoul). 2012; 20(2): 152–157.
    CrossRefPubMed
  32. Rao JS, Ertley RN, Lee HJ, et al. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry. 2007; 12(1): 36–46.
    CrossRefPubMed
  33. Akbar M, Calderon F, Wen Z, et al. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A. 2005; 102(31): 10858–10863.
    CrossRefPubMed
  34. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005; 115(10): 2774–2783.
    CrossRefPubMed
  35. Mukherjee PK, Marcheselli VL, Serhan CN, et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. 2004; 101(22): 8491–8496.
    CrossRefPubMed
  36. Gamoh S, Hashimoto M, Sugioka K, et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience. 1999; 93(1): 237–241.
    PubMed
  37. Gamoh S, Hashimoto M, Hossain S, et al. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol. 2001; 28(4): 266–270.
    PubMed
  38. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem. 2004; 90(4): 979–988.
    CrossRefPubMed
  39. Holmquist L, Stuchbury G, Berbaum K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther. 2007; 113(1): 154–164.
    CrossRefPubMed
  40. Hooijmans CR, Pasker-de Jong PCM, de Vries RBM, et al. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2012; 28(1): 191–209.
    CrossRefPubMed
  41. Cao D, Kevala K, Kim J, et al. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem. 2009; 111(2): 510–521.
    CrossRefPubMed
  42. Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience. 2006; 139(3): 991–997.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl